Mithu Maheswaranathan, MD

Dr. Mithu Maheswaranathan is a rheumatologist at Duke University School of Medicine. He has an interest in digital medical education and health literacy. He is the creator of “Rheum OnePagers,” infographics to explain and simplify rheumatology.  He also has a special interest in systemic lupus erythematosus (lupus) and is involved in clinical and collaborative research efforts as part of the Duke Lupus Clinic.

Articles by Mithu Maheswaranathan, MD

Mithu Maheswaranathan, MDRheumatoid Arthritis | March 6, 2024
A case series presented data on the efficacy of CAR T-cell treatment in patients with rheumatic autoimmune disease.
Read More
Mithu Maheswaranathan, MDOsteoarthritis | February 5, 2024
It is critical for physicians to be confident and comfortable in diagnosing and managing knee osteoarthritis.
Mithu Maheswaranathan, MDRheumatology | December 22, 2023
Mithu Maheswaranathan, MD, spoke about challenges, treatments, and trends in rheumatology, as well as upcoming advancements.
Mithu Maheswaranathan, MDRheumatology | December 6, 2023
A study aimed to create a benefit-versus-harm shared decision-making tool for hydroxychloroquine for patients with SLE.
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
A study provided a unique characterization of a rare: large-vessel involvement from ANCA-associated vasculitis.
Mithu Maheswaranathan, MDRheumatoid Arthritis | October 11, 2023
A study sought to identify variables distinguishing inflammatory from noninflammatory arthritis in a large cohort.
Mithu Maheswaranathan, MDRheumatoid Arthritis | October 11, 2023
Ultra-low dose rituximab significantly reduced the rate of infections versus the standard low dosage in rheumatoid arthritis.
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
Researchers examined changes in objective measures of cardiorespiratory function and patient-reported outcomes in lupus.
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
A study sought to characterize racial differences in lupus clinical manifestations.
Mithu Maheswaranathan, MDRheumatoid Arthritis | October 11, 2023
Results of the ORAL Surveillance study were recently published in the NEJM in late January 2022.  ORAL Surveillance was ...
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
Dr. Mara Becker spoke on the management of adults with JIA including uveitis and macrophage activation syndrome.
Mithu Maheswaranathan, MDRheumatology | October 11, 2023
The debate discussed benefits and drawbacks of these two agents. See why Dr. Michelle Petri argues in favor of belimumab.